Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 20/20 | 0.55 |
| ▸ | FLT1 | P17948 | 6/20 | 0.53 |
| ▸ | FLT4 | P35916 | 6/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27721052 | 0.87 | EGFR (0.47) | KDRFLT1FLT4 | |
| SCHEMBL27741871 | 0.87 | KDR (0.45) | KDRFLT1FLT4 | |
| SCHEMBL27721058 | 0.86 | KDR (0.52) | KDRFLT1FLT4 | |
| SCHEMBL1654672 | 0.81 | PTGS2 (0.47) | KDRFLT1FLT4 | |
| SCHEMBL3359085 | 0.81 | TGFBR1 (0.42) | KDRFLT1FLT4 | |
| SCHEMBL17918815 | 0.79 | BRAF (0.38) | KDRFLT1FLT4 | |
| SCHEMBL27741887 | 0.78 | KDR (0.40) | KDRFLT1FLT4 | |
| SCHEMBL17918831 | 0.77 | ALDH1A1 (0.53) | KDRFLT1FLT4 | |
| SCHEMBL27721057 | 0.76 | KDR (0.36) | KDRFLT1FLT4 | |
| SCHEMBL6295327 | 0.76 | KDR (0.62) | KDRFLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1255406-C | Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods | ORTHO MCNEIL PHARM INC (US) | 2006-05-10 | — | — | CN | claimed |
| CN-1342162-A | Substituted 2-acyl-3-(heteroaryl)-imidazo [1,2-a] pyrimidines, and related pharmaceutical compoistions and methods | ORTHO MCNEIL PHARM INC (US) | 2002-03-27 | — | — | CN | claimed |
| CN-101291582-A | Novel imidazo based heterocycles | ABBOTT LAB (US) | 2008-10-22 | — | — | CN | disclosed |
| US-6958340-B2 | such as N-[3-methyl-5-(trifluoromethyl)phenyl]-4-(2-phenyl-1H-imidazol-1-yl)pyrimidin-2-amine; treating breast cancer; use in combination with estrogen receptor modulators such as tamoxifen and raloxifene | MERCK & CO., INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040220201-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-11-04 | — | — | US | disclosed |
| WO-2003011836-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220201-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885FLT1 4/4885FLT4 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.